L. Williams

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir , an Inhibitor of Hepatitis C Virus NS 5 A

A. Molla, T. Pilot‐Matias, T. Reisch, 2015 .

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

A. Molla, T. Pilot‐Matias, T. Reisch, 2014, Antimicrobial Agents and Chemotherapy.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

A. C. Krueger, A. Molla, T. Pilot‐Matias, 2014, Journal of medicinal chemistry.

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

T. Pilot‐Matias, W. Xie, E. Lawitz, 2012 .

Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers

S. Dutta, K. Sommerville, D. Selness, 2002, Epilepsy Research.

1204 PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV NS5A INHIBITOR ABT-267 FOLLOWING SINGLE AND MULTIPLE DOSES IN HEALTHY ADULT VOLUNTEERS

S. Dutta, T. Podsadecki, R. Menon, 2011 .

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

T. Pilot‐Matias, T. Marbury, W. Xie, 2012 .

Realworld Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic Hepatitis C: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts

S. Pungpapong, B. Aqel, D. Wyles, 2016 .